These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 15094887)
1. [Low molecular weight heparins: mechanisms of action and pharmococynetics. Clinical advantages over the classic unfractioned heparins]. Campos M Rev Port Cir Cardiotorac Vasc; 2003; 10(2):61-7. PubMed ID: 15094887 [TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin in the treatment of pulmonary embolism. Ageno W; Turpie AG Semin Vasc Surg; 2000 Sep; 13(3):189-93. PubMed ID: 11005462 [TBL] [Abstract][Full Text] [Related]
3. [New medical anticoagulants]. Choussat R; Montalescot G Rev Mal Respir; 1999 Nov; 16(5 Pt 2):985-95. PubMed ID: 10907447 [TBL] [Abstract][Full Text] [Related]
4. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137 [TBL] [Abstract][Full Text] [Related]
5. Clinical and economic impact of low-molecular weight heparins in managed care. Introduction. Am J Manag Care; 2000 Nov; 6(20 Suppl):S1024-5. PubMed ID: 11484301 [No Abstract] [Full Text] [Related]
6. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes. Haas S Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477 [TBL] [Abstract][Full Text] [Related]
7. New-generation anticoagulants: the low molecular weight heparins. Hovanessian HC Ann Emerg Med; 1999 Dec; 34(6):768-79. PubMed ID: 10577408 [TBL] [Abstract][Full Text] [Related]
8. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke. Padma V; Fisher M; Moonis M Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101 [TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins: the optimal treatment for venous thromboembolism. Daskalopoulos ME; Daskalopoulou SS; Liapis CD Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244 [TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparins in cardiovascular medicine. De Lorenzo F; Dotsenko O; Kakkar VV Minerva Cardioangiol; 2005 Dec; 53(6):585-603. PubMed ID: 16333240 [TBL] [Abstract][Full Text] [Related]
13. Update in the treatment of venous thromboembolism. Garcia DA; Spyropoulos AC Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085 [TBL] [Abstract][Full Text] [Related]
14. Heparin: from animal organ extract to designer drug. Middeldorp S Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279 [TBL] [Abstract][Full Text] [Related]
15. The treatment of deep venous thrombosis, including the newer agents. Rectenwald JE; Wakefield TW Dis Mon; 2005; 51(2-3):104-11. PubMed ID: 15900261 [No Abstract] [Full Text] [Related]
16. Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease. Gallieni M; Cozzolino M; Ronga C; Brancaccio D Nat Clin Pract Nephrol; 2008 Sep; 4(9):488-9. PubMed ID: 18612327 [No Abstract] [Full Text] [Related]
17. Low-molecular-weight heparins: beyond thrombosis in the management of the cancer patient. Kakkar AK Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():13-5. PubMed ID: 14730473 [TBL] [Abstract][Full Text] [Related]
18. Management of deep vein thrombosis in cancer patients. Jahanzeb M J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S50-3. PubMed ID: 16280114 [No Abstract] [Full Text] [Related]
19. Low-molecular-weight heparins during pregnancy. Many A; Koren G Can Fam Physician; 2005 Feb; 51(2):199-201. PubMed ID: 15751560 [TBL] [Abstract][Full Text] [Related]
20. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Kher A; Bauersachs R; Nielsen JD Thromb Haemost; 2007 Apr; 97(4):505-13. PubMed ID: 17393011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]